Earnings call transcript: Healwell AI reports strong Q2 2025 growth

Healwell AI (AIDX) reported a significant increase in revenue and profitability for the second quarter of fiscal year 2025, driven by strong performance in its healthcare software segment. The company’s stock surged 13.57% following the earnings announcement. According to InvestingPro analysis, the company is currently trading above its Fair Value, with a market capitalization of $280.8 million. InvestingPro data shows impressive revenue growth of 388.62% over the last twelve months.

Key Takeaways

• Revenue for Q2 FY2025 was $40.5 million, marking a 645% year-over-year increase.
• First profitable EBITDA quarter, reaching $1.9 million compared to a loss of $3.7 million in Q2 2024.
• Gross margin improved to 52.5%, up from 45.2% the previous year.
• Full acquisition of Pentavir and integration of Orion Health’s platform.
• Stock price rose by 13.57% following the earnings call.

Company Performance

Healwell AI showcased robust growth in Q2 FY2025, with revenue surging by 645% year-over-year to $40.5 million. This growth was largely fueled by its healthcare software segment, which posted a 1,062% increase. The company also reported its first profitable EBITDA quarter, reflecting successful cost optimization efforts and strategic acquisitions, such as the full acquisition of Pentavir.

Financial Highlights

• Revenue: $40.5 million (645% YoY increase)
• EBITDA: $1.9 million (compared to -$3.7 million in Q2 2024)
• Gross Profit: $21.2 million (764% YoY increase)
• Gross Margin: 52.5% (up from 45.2% in Q2 2024)
• Cash Position: $19 million (up from $9.4 million in Q4 2024)

Market Reaction

Following the earnings announcement, Healwell AI’s stock experienced a significant increase, rising by 13.57% to $1.59. This movement reflects investor confidence in the company’s strategic direction and financial performance. InvestingPro analysis reveals that the stock has a beta of -1.04, meaning it tends to move in the opposite direction of the broader market, which could make it an interesting diversification option. The stock’s current price is closer to its 52-week high of $2.36, indicating a positive market sentiment. Analyst targets range from $1.82 to $3.63, suggesting potential upside opportunities.

Outlook & Guidance

Looking ahead, Healwell AI aims to achieve 100% year-over-year revenue growth in its AI and Data Science segment. The company is exploring strategic alternatives for its clinical and patient service businesses and is actively seeking mergers and acquisitions in data science and new geographical markets. Healwell AI also aims to be EBITDA positive for the full year 2025.

Executive Commentary

CEO James Lee emphasized the company’s strategic shift, stating, "We’re moving from a collection of strong individual platforms to a unified AI powered healthcare solution." President Alexander Domonoske added, "We believe that we have now the necessary building blocks in place. It’s the time to plant our flag as a leader in healthcare AI."

Risks and Challenges

• Integration Challenges: The integration of new acquisitions like Pentavir and Orion Health’s platform could present operational challenges.
• Market Competition: Increasing competition in the digital health market could impact market share.
• Regulatory Risks: Navigating regulatory environments in different regions could pose challenges.
• Economic Conditions: Global economic instability might affect healthcare spending.
• Technological Changes: Rapid advancements in AI technology require continuous innovation.

Healwell AI’s Q2 2025 performance highlights its strategic focus on expanding its AI capabilities and healthcare software offerings. The company’s strong financial results and positive market reaction underscore its potential for future growth in the rapidly evolving digital health market. InvestingPro subscribers can access 6 additional key insights about Healwell AI, along with comprehensive financial health scores and a detailed Pro Research Report, which is part of our coverage of over 1,400 US equities. The company maintains a healthy current ratio of 3.79, indicating strong short-term liquidity position, while analysts anticipate continued sales growth in the current year.

Full transcript - Healwell Al Inc (AIDX) Q2 2025:

Conference Operator: Good morning and thank you for joining Hewwell AI’s Second Quarter twenty twenty five Financial Results Conference Call. All participants are in a listen only mode and the call is being recorded. I will now turn the call over to Hefton Seni, Investor Relations at Heol. Please go ahead.

Hefton Seni, Investor Relations, Hewwell AI: Hello. Thank you, operator. Joining me on the call today are James Lee, CEO of Doctor. Alexander Domonoske, President of Hewol and Amsley Lam, Hewol’s CFO. I trust that everyone has received a copy of our financial results press release that was issued earlier today.

Listeners are also encouraged to download a copy of our quarterly financial statements and management discussion analysis once filed on SEDAR plus Please note portions of today’s call other than historical performance include statements of forward looking information within the meaning of applicable securities laws. These statements are made under the Safe Harbor provisions of those laws. Please refer to today’s press release and to our management discussion and analysis for more details on the company’s risk and forward looking statements. We provide forward looking statements solely for the purpose of providing information about management’s current expectations and plans relating to the future. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward looking statements to reflect any change in our expectations or any change in events, conditions, assumptions or circumstances on which any such statement is based, except if it is carved by law.

We use terms such as gross margin and adjusted EBITDA on this call, which are non IFRS and non GAAP measures. For more information on how we define these terms, please refer to the definitions set out in our management discussion analysis. There will be a question and answer session at the end of the call, which will be limited to analysts only. To ask a question, analysts are required to call in to the conference call using the dial in number provided in our press release. And with that, let me turn over the call to James Lee, CEO.

James Lee, CEO, Hewwell AI: Thank you, Heathen. Good day to everyone. I really appreciate you all joining us for our second quarter conference call. On today’s call, I’m going focus on three key topics. Firstly, Q2, obviously, the growth momentum and EBITDA profitability.

Secondly, as you’d have seen, QL intends to transition to be a pure play AI software and services business. And finally, I’ll touch on our growth, integration and future global expansion. To begin with, let’s start with Q2. Q2 was a breakout quarter for AOL. We achieved the highest ever quarterly revenue of 40,500,000.0 reflecting an increase of six forty five percent year on year increase.

More importantly, we achieved adjusted EBITDA of $1,900,000 making our first profitable EBITDA quarter since the company was launched in 2023. This is not just a financial achievement, but signifies a key milestone in our journey to becoming a world leading AI and data science and healthcare software platform. This quarter, we’ve seen firsthand the power of our strategy. We’ve scaled efficiently. We’ve levered our AI and data science strengths, and we’ve delivered, more importantly, lasting real value to the health care system.

Our strategy is working, and we’re seeing continued momentum across our key business lines. Q2 marked an inflection point for HUGO, both in terms of financial results, but equally, the operational rigor and discipline behind them. The standout driver for the quarter was successful completion of the Orion Healthcare acquisition on April 1. This acquisition had an immediate and material impact for us. It’s contributed meaningfully to the top line.

Orion itself fueled 1064% growth in our Hewell Healthcare Software segment, and it’s a genuine validation of the strategy we’ve got to acquire high quality and accretive value adding acquisitions. But our growth extends well beyond Iran. Our core AI business, as you’ve seen previously, has delivered strong results, reflecting an increase in both the clinical validation and the enterprise grade AI software that we have in the Healthcare segment. In the 2025, our AI segment generated over $5,000,000 of revenue. But beyond the numbers, Q2 reflects a fundamental shift in how we’re rebuilding Pure World.

We’re actively reshaping the structure of the company, streamlining our focus, realigning around our core strengths and laying the foundation for long term international scale and profitability. This transformation is not just strategic, it’s structural. We’re evolving how we organize, operate and report on our business to better reflect our focus on AI and healthcare software. As you’d have seen today, the second topic I want to cover is the reshaping of our identity to a pure play AI and software company. As we grow, we’re aligning down those two key divisions.

This strategic realignment is about focus, ensuring every part of the company is contributing to our long term vision of becoming a pure play AI and software business. And to that end, the Board of Directors have decided to seek strategic alternatives for the company’s clinical and patient service business units with the goal to become a pure play software business. Recently, the company signed a number of nonbinding LOIs to investigate this effort.

: Our strategy is clear: We’re

James Lee, CEO, Hewwell AI: a preventative health care AI company that uses technology to connect and surface complex health care data. We provide clinically validated tools to analyze that data to both enhance the efficiency and accuracy of it. We’re embedded in over 70 health care systems globally, and we’re focused on deepening our relationships with those existing customers and also expanding the number of health care systems we serve. And finally, I want to talk briefly about our strategy to grow and integrate. We’ve evolved significantly in the past year.

And with our foundation now firmly set, we’re entering a new phase of business. Our goal is to bring a high margin software and services company anchored in data science and AI and continue to extend our reach into world’s largest health care systems. To support that vision, we are actively building what we believe will not just be Canada’s largest and most important healthcare focused AI platform, but one that is globally relevant. While embedding advanced AI directly into clinical applications, we’re creating a unified end to end solution that sets us apart. There are very few companies globally that bring both the data science knowledge and healthcare expertise that we can to a single platform.

The acquisition of Orion Healthcare has accelerated this. We’re moving quickly to integrate the platforms. And so far, the results have exceeded the expectations. Orion brings decades of experience in one of the world’s most advanced healthcare data infrastructure, along with a global footprint of 70 enterprise customers across 11 countries. Today is a pivotal step in Herewell’s evolution.

We’re moving from a collection of strong individual platforms to a unified AI powered healthcare solution,

: and

James Lee, CEO, Hewwell AI: today is only the beginning. And with that, I’d like to hand over the call to our CFO, Anthony Lamb, to walk through our Q2 results. Over to you, Anthony.

Anthony Lamb, CFO, Hewwell AI: Thank you, James.

Anthony Lamb, CFO, Hewwell AI: Before I begin, I’d like to remind everyone that all of the figures I’ll be discussing today are in Canadian dollars and our financial statements are presented in accordance with IFRS International Financial Reporting Standards. Our second quarter twenty twenty five results are as follows. Hewol achieved quarterly revenues of $40,500,000 during Q2 twenty twenty five compared to revenue of $5,400,000 generated in 2024. This is an increase of 645%. Revenue growth in the quarter was primarily driven by the Orion acquisition resulting in a 1064% year over year increase in the company’s healthcare software business compared to the prior year.

KOL achieved gross profit of $21,200,000 in Q2 twenty twenty five. This is an increase of 764% compared to $2,500,000 during 2024, sorry. The increase is due to the acquisitions of Verisource, Mutual and Orion and strong performance in the Cure business. Hillwell’s gross margin percentage in Q2 twenty twenty five was 52.5. This compares to 45.2% in Q2 twenty twenty four.

The increase in gross margin percentage is due to the addition of higher margin healthcare software revenue from the Orion acquisition. During Q2 twenty twenty five, Healwell reported positive adjusted EBITDA of $1,900,000 and this compares to adjusted EBITDA loss of $3,700,000 in Q2 twenty twenty four. This marks the company’s first quarter of positive adjusted EBITDA, reflecting strong operating leverage and business momentum. This turnaround represents a year over year improvement of approximately 152 in adjusted EBITDA performance. EOL also reported $6,000,000 in net loss in Q2 twenty twenty five and this compares to $2,500,000 loss in Q2 twenty twenty four.

Hewel ended the quarter on 06/30/2025 with $19,000,000 in cash, an increase as compared to $9,400,000 at the end of Q4 twenty twenty four. Today, QOL generates revenue across three core segments. One, AI and data science two, healthcare software and three, clinical research and patient services. Our AI and data science segment achieved revenue of $2,700,000 in Q2 twenty twenty five marking an impressive 221% year over year growth compared to Q2 twenty twenty four. This growth was driven by healthy organic growth and the mutual acquisition.

During Q2, we also had one large AI related project that bolstered revenues in the quarter which is not expected to repeat in Q3. The second revenue stream is healthcare software which generated 30,400,000.0 in revenue for Q2 twenty twenty five. This is an increase of 1062% from $2,600,000 in the same period last year. Growth was primarily driven by the acquisition of Orion Health. The third revenue segment of Clinical Research and Patient Services generated $7,200,000 of revenue reflecting a 231% increase compared to Q2 twenty twenty four driven by our acquisition of BioPharma.

With our Clinical and Patient Services segment, we continue to transition BioPharma from preclinical to early stage and later stage clinical trials. This transformation is expected to enhance profitability and align the business with higher margin opportunities. However, biopharma is expected to experience a decline in revenue in the near term through this transition period. Looking forward, the strategic review of polyclinic and biopharma businesses, this may result in Hewah reducing its reporting segments from three down to two core segments AI and healthcare software. With that, I’d like to turn the call over to our President, Doctor.

Alexander Dubronowski to walk you through our integration, outlook and goals for 2020.

Alexander Domonoske, President, Hewwell AI: Thank you, Anthony, very much and thank you, James and good day everyone. I’d like to begin by discussing the exciting progress we’ve made with integration and our growth strategy. The integration of Orion Health into our business has been a transformative milestone for HealWell in Q2, enabling us to innovate at this intersection of data interoperability and artificial intelligence. Since the acquisition, we have made significant progress in merging our teams, technologies and platforms creating powerful synergies across our healthcare software and AI business units. This methodical integration has already delivered financial contributions, particularly within our healthcare software segment.

Looking ahead, as we transition away from clinical and patient services, we expect AI and healthcare software to represent 100% of our total revenue positioning Heal well as a global leader in healthcare AI. With Orion’s extensive worldwide reach and robust data infrastructure, we are well positioned to expand our AI capabilities and accelerate growth in both existing and new markets. Our current operations strategy is focused on six key areas. One, cost optimization. Earlier this year we announced a cost optimization program which has already benefited the company in aligning its operations to this new strategic direction even prior to the closing of the Orion Health acquisition.

The company has now entered a post closing phase of this cost optimization initiative in which we are identifying and actioning additional synergies. Two, shared services infrastructure. We have now established a unified corporate level framework for HR, finance, marketing, legal, IT and cyber enabling these resources to be leveraged across our entire group of businesses for greater efficiency. Three, consolidation of our healthcare software segment. We are bringing together Orion, Verisource and IntraHealth into one cohesive healthcare software segment.

Orion and Verisource are particularly complementary creating a stronger platform for innovation and delivery of healthcare data infrastructure capabilities to clients around the globe. Four, tighter integration of AI assets. As you would have seen subsequent to quarter end, Healwell acquired the remaining portion of Pentavir that it did not previously own and now with full 100% ownership of Pentavir, we are enhancing our ability to leverage its globally validated capabilities alongside Cure Health to deliver advanced AI powered solutions that identify at risk patients and gaps in care delivery, accelerating clinical research and real world evidence generation. Five, embedding AI into Orion’s global platform and this is part of the industrial logic of the acquisition of Orion Health. We are integrating Heal Wall AI technologies such as clinical search, patient data summarization, patient risk stratification and real world evidence generation directly into Orion’s software suite.

This allows us to deliver end to end AI powered solutions without requiring customers to replace their existing systems ensuring adoption at scale. We believe this is a globally unique and competitive advantage of our offering. Beta proof of concepts for AI enabled clinical search and summarization are currently underway showcasing the value of our integrated solutions in active customer settings. Leveraging Orion’s presence in 11 countries and its established healthcare infrastructure, we are accelerating our global expansion and positioning Hewalt to deliver scalable AI powered healthcare solutions worldwide. We are already seeing strong early demand for our integrated solutions, particularly in The U.

S. Market. To address the unique needs of The U. S. Healthcare system, part of a digital health market projected to reach $695,000,000,000 in 02/1933, we have introduced modular AI tools that support value based care, population health management and operational efficiency.

As these integrations mature, we expect to unlock meaningful recurring revenue streams across both our AI and Healthcare Software segments. This combination of advanced AI technologies, a unified software platform and global market reach provides a strong foundational foundation for sustained profitable growth. I’ll now talk about our positive outlook and goals for the remainder of 2025. Looking ahead and as James has already shared, our goals are clear and aligned with the broader vision of becoming a high margin AI and SaaS software leader in healthcare. Our revenue and profitability saw substantial growth reflecting the effectiveness of our strategy and the progress we’ve made across all business units.

With the support of our cost optimization initiatives and the positive financial contributions from Orion, we are still firmly on track to be adjusted EBITDA positive for the full year in 2025. For our segmented performance, we remain on track to achieve our stated goal of 100% year over year revenue growth in our AI and Data Science segment compared to last year. Our Healthcare Software segment can experience variability due to fluctuations in professional services revenue. In Q2, professional services revenue was exceptionally strong driven by certain one time projects that are expected to be lower in Q3. Now for the remainder of 2025, we are focused on achieving the following goals.

Further integration of our core businesses across both the AI and healthcare software business segments and we’re continuing to harmonize our platforms, cross leverage data and ensure that our teams work seamlessly together across the globe. By the end of the year, we expect to see full synergy. Executing on strategic M and A, our acquisition pipeline includes both AI and healthcare software opportunities and we are currently in deep discussions with two potential acquisition targets with one executed non binding LOI. Increasing organic growth, we are ramping up our organic growth efforts by accelerating the adoption of Healwell’s AI solutions not just with our life sciences partners, but across the entire healthcare ecosystem. We are looking at cross sell and upsell opportunities between our healthcare software segment and our AI and data science segment.

This is core to our strategy. We are already bidding on contracts that combine elements of our healthcare software and AI offerings. Expansion within the Well Health ecosystem. Our important strategic partnership with Well Health has proven to be an exceptionally powerful catalyst for growth. We’re working closely with Well to deepen our integration across their network of clinics and healthcare providers, capitalizing on the Canadian market and global reach.

We’re leveraging our strong foundation in Canada. We will continue to develop the Buy Canadian initiative focused on opportunities within the Canadian healthcare market while expanding globally. With Well Health support, we’re well positioned to drive adoption of our AI solutions and software not only in Canada, but in international markets, in The U. S, Europe and The Middle East. These goals will guide our efforts as we enter the 2025 with a focus on sustainable profitable growth.

We are confident that we are building something truly transformative here at Healwell. We’ve made remarkable progress in a short period and the opportunities ahead of us are immense. In closing, I want to reiterate that Healwell is a healthcare artificial intelligence company that has proven results and is a leading example of AI being used in production at scale globally. Going forward, Healwell plans to transition into a pure play SaaS software and services company with a focus on AI and data science. Over the past twenty two months Healwell has witnessed tremendous growth as we’ve grown from a company that was doing $7,000,000 in annual revenue, losing money to achieving now approximately $160,000,000 annualized revenue run rate in the second quarter and an EBITDA positive business.

M and A will continue to play a significant role at Healwell going forward with a focus on AI and healthcare software related tuck in opportunities. We believe that we have now the necessary building blocks in place. It’s the time the time is now to plant our flag as a leader in healthcare AI not just in Canada, but from a global perspective. Finally, I’d like to thank the entire team at Healwell, particularly also our executive team whose hard work continues to elevate the company to higher levels. I’d like to thank all our investment banking partners, the capital markets community.

I’d like to thank our Chairman, Hamed Shibazi and the leadership team at Well Health. Plus, I’d like to thank our Board of Directors and I’d like to thank you all for joining us on this call today. James, Anthony and I look forward to providing an exciting update next quarter. Now I’ll hand it back to the operator.

Conference Operator: Thank you. We will now begin the analyst question and answer session. And your first question today will come from Daniel Rosenberg with Paradigm Capital. Please go ahead.

Daniel Rosenberg, Analyst, Paradigm Capital: Hi, good afternoon. Thanks for taking my question. Congrats on the strong quarter and the acquisition. I guess my first one is around the integration of the acquisition and your go to market. Was wondering now that you’re further consolidating your teams, how does that go to market look like whether you’re bidding for RFPs?

Or do you have a direct sales team? Are you looking for pilots? Any color there would be appreciated.

James Lee, CEO, Hewwell AI: Thanks, Daniel. It’s James. I guess the answer is a bit of everything. We’ve got in motion pilots already in new markets. We’ve got proof of concepts in markets, and we’re responding to many RFPs as a combined unit.

What we’re finding is that the teams working really well and that we’re seeing opportunities across each of our business lines to combine an RFP responses given the increased capability we have across the group. So we’re seeing that across each part of our both software and AI businesses.

Daniel Rosenberg, Analyst, Paradigm Capital: Good to hear. Thanks for that color. I was also curious around you spoke about new markets. Any specific geographies of interest? I think you highlighted The U.

S. As a large opportunity for you. So the world is a big place, but just trying to figure out where you’re targeting in on.

James Lee, CEO, Hewwell AI: That’s a really good question. I think what we’re seeing right now is that AI adoption in The U. S. Is picking up pace. But as you said, it’s a very big market.

So we’ve already got pilots working in The U. S, which is exciting. One of the markets that we’re seeing opportunity in is the NHS in England just announced a new ten year plan to digitize first their entire health care system. Now while that is a we’re only into the early months of that ten year plan, What it means for us is there’s a real opportunity for us to spend a lot of time in that market. It’s a very big market.

It’s 50% bigger than Canada. And it’s a lot more complex, which works for us given that we cover a big portion of it currently. As opposed to new markets, we’ll be very careful into new environments. What we’re seeing is that there’s plenty of opportunity both in The Middle East, Southeast Asia and Europe. But what we’re trying to do currently is focus on our key markets we have in front of us today to ensure we’re delivering for our shareholders first.

Daniel Rosenberg, Analyst, Paradigm Capital: Would it be possible to dig a bit deeper on those U. S. Modular opportunities? Like any specific areas of healthcare where you’re thinking you could apply your technologies into new growth avenues?

James Lee, CEO, Hewwell AI: Yes. Look, they’re probably all of our products have fit in The U. S. Market. So we’re seeing opportunities with a Firebase repository in The U.

S. We’ve got both within our Smart Identify and our Smart Search capabilities in The U. S. And through subtraction layers. The reality is all of our products have fit.

I think the focus on value based care works in our favor in the short to medium term. And so the ACO market is a clear opportunity for us as well.

Daniel Rosenberg, Analyst, Paradigm Capital: Last for me, just a financial one. You set out some goals for your annual targets. I was wondering on the balance sheet, how we could think about if you had any targets in terms of ratios, debt levels, etcetera, that you could share with us? And I’ll pass the line.

James Lee, CEO, Hewwell AI: Look, I guess the answer, Daniel, that is given the process we’re going through with our clinical business right now, we’re reviewing all those what our needs be without their clinical businesses. So we’ll have to come back at a later date on that. We’ve only had those for a few weeks.

Daniel Rosenberg, Analyst, Paradigm Capital: Okay, fair enough. Thanks for taking my questions. I’ll pass the line.

Conference Operator: And your next question today will come from Kevin Krishnaratne with Scotiabank. Please go ahead.

Kevin Krishnaratne, Analyst, Scotiabank: Hey there. Good afternoon. Congrats on a nice quarter here. First, I just had a quick clarification. I think you mentioned that your healthcare software business benefited from variability in pro services.

Can you remind us like how much of the healthcare software line is PS and sort of what drove that one time benefit? Is that for a future project? And do we see a ramp up in related software revenue in coming quarters? Just any sort of color there you can talk about on the PS line.

James Lee, CEO, Hewwell AI: Sure. Look, I think professional services is a broad is sort of a 20%, 24% range of software revenue across the business. And the variability really, Kevin, is not so much as the amount of work, but actually the delivery cycle. Orion is a really lumpy business. And so when you hit milestones, you need to recognize the revenue.

And so what we’ll see is we’ll see some volatility quarter by quarter as to when certain milestones are hit, whether they’re hit at the end of the quarter or the start of the next one is when we get to recognize the revenue while the workload is even across the year. Does that make sense?

Kevin Krishnaratne, Analyst, Scotiabank: It does. And just to help us just understand the profile this quarter then you did talk that there are some onetime projects. Any way to quantify that for the quarter?

James Lee, CEO, Hewwell AI: Look, I think the reality is that what works with this quarter specifically, but they’re in the single million dollar movements between quarter by quarter. They’re not tens of millions of dollars to give you context.

Kevin Krishnaratne, Analyst, Scotiabank: Got it. That’s helpful because the next question I had is just I understand that the way you’re running your business is you’ve got your healthcare software business, the HIE business and you’ll be cross selling AI and data products that you’ll book in your AI and data bucket. But if I just turn back to thinking about the healthcare software business and sort of organic growth over the next coming quarters, years, what’s like a good level? Like what do you think you talked about your near term targets for the year. Like can you just remind us again what you’ve got kind of got contemplated for the organic growth and sort of how that is what’s the algorithm for that growth pricing, new logos, expansion, just any color there on the organic growth for healthcare

James Lee, CEO, Hewwell AI: software? Yes. Look, Kevin, as we’re putting the business together, you need to give us a bit of time to come back with a cleaner number on that. But what I’ll tell you is about the drivers of that growth. So there are three key drivers.

Obviously, new logos. So we’ve seen clear desire to increase the number of logos we have across the platform. The second is the number of applications we have per logo. And the third is the size of each of those contracts per application. And so as we think about the key drivers of the business, we see three key factors.

Are we growing the number of logos? Are we growing the number of deployments per logo? And are we growing the number of the value of those deployments. But as we start integrating those business lines, they’re all going have different measures. So we want to come back with a really clear sense of to give people what the business should look like long look forward and how you should think about modeling it going forward.

Kevin Krishnaratne, Analyst, Scotiabank: That’s super helpful, James. Maybe just the last one then. You did talk about a couple of things. You’re responding to RFPs now with your good and combined go to market team. You talked about some of the products you have you believe are unique in market.

And so when you think about those RFPs and the value prop that you’re showing on these RFPs. Is that for new logos? Are these sort of hospital networks in various states and provinces that are kind of up for renewal with their existing provider and then looking to switch and you’re running into an RFP there. Can you just talk about what you’re seeing out there and what these bids really what you’re actually bidding on? And again, talked about the uniqueness of your products.

I’m just really curious to think about how well you are positioned against the other competing products out there.

James Lee, CEO, Hewwell AI: Yes. Look, again, look, excellent question and a really complex answer. So I’ll try to be simple. But look, what we’ve seen is say yes to all as the real answer. So what we’ve seen is our existing customers, now that they’re asking to see what our AI capabilities are, can ask us for RFPs on certain products.

That works both across our AI topics, but also going into things like patient identification, which are used in population health management. The scale of those opportunities is enormous. The reality is that as you get close to value based here, the value of those contracts can be material. We’re also seeing opportunity with new logos as the world tries to digitize its platform. So as you can imagine, we’re seeing AI being required, they need new infrastructure.

And so each part of our business have got deep pools of RFPs. The way we could sort of think about it is that a new installation is probably one times PSG, one times recurring revenue for a population of less than 5,000,000 But those numbers scale up materially post that.

Kevin Krishnaratne, Analyst, Scotiabank: Got you. Thanks a lot, James. I’ll pass the line. Appreciate it.

Conference Operator: And your next question today will come from Gianluca Tucci with Haywood Securities. Please go ahead.

Gianluca Tucci, Analyst, Haywood Securities: Hi, good afternoon team. Congrats on a nice quarter. If I could just ask on the early days of cross selling, AI bucket for the first half is up over 200%. Does that include any early cross sell deals that have closed? And as follow-up, could you speak to the average deal size in your AI pipeline and how that’s been trending over the last call it six to twelve months?

James Lee, CEO, Hewwell AI: Look, excellent question, John Luke. The answer to that is no. There have been no cross sells. That’s too early. The business is only going three months and the RFP process from RFPs are closed.

Implementation, as you can imagine, is well longer than a three month process. So you’ll see that benefit coming into the market either late this year or early next. What I would suggest is that what we’ve seen is the size of our contracts over the last twelve months have been increasing on a consistent basis as we add more data to them. The RFP opportunities we see today range by population size, so I won’t give a number today. But I think it’s fair to say that the opportunity for some of these are across very large populations, which would be material contracts if they won.

Some of them the larger ones will be long dated. Our focus currently is actually getting them embedded and installed, and then installing more features as we go along. So rather than take a long time to get something in market, we’re very focused on getting a proof of concept going to prove value and then increase our share of wallet as we move into the customer. Is there anything you want to add to that Anthony or Alex?

Alexander Domonoske, President, Hewwell AI: No, James, I think you touched on the salient points. I’ll just add Gianluca, right, like we’ve seen steady growth, right, from an AI perspective on the size of the initiatives and contracts, right, with our life sciences partners. So that’s moving in very productive direction. And we’re anticipating, right in coming quarters us to be able to highlight some of these proof of concepts right that we’re working on right now which is of course harnessing our software footprint.

Gianluca Tucci, Analyst, Haywood Securities: Okay. That’s great color. Thank you guys. And just secondly on the plan to divest your clinical research business, could you speak at a higher level perhaps to the immediate margin benefit that would have? And what do you think your overall consolidated margins can scale to excluding the CRO business going forward?

James Lee, CEO, Hewwell AI: Look, the reality is that we’re in very early discussions on that now and we’re only doing that work as we’re speaking. So we’ll have to come back to you on that. And I think the reality is the shape of what we do within the various LOIs means that it’s a longer conversation for other time. Is there anything you want to add to that Anthony?

Anthony Lamb, CFO, Hewwell AI: Yes, James. I think look, as you can see right now our AI and software businesses are in the high 60s in terms of margin. We’re seeing mid to high 50s in our software business. So we’re going to be in that range based on mix. We’re going to see some really good software like performance in our margins.

But I mean we are going to be focusing on that and you can expect us to be in that high 50 to low 60 range as a result.

Gianluca Tucci, Analyst, Haywood Securities: Okay, great color. Thank you guys.

James Lee, CEO, Hewwell AI: Thanks, Gianluca.

Conference Operator: And your next question today will come from Brian Kinstlinger with Alliance Global Partners. Please go ahead. Brian, your line may be muted. It’s open on our end.

Hefton Seni, Investor Relations, Hewwell AI0: Sorry about that. I apologize I was on mute. Thanks for taking my question. I realize your guidance suggests a doubling of revenue for AI and data science this year, but it’s based on relatively small numbers. So my question would be, what are the gating factors to exponential growth from here where you are in the first half of the year?

Is it new customer adoption, greater usage from existing customers, more diseases? I guess maybe what drives this to be two to three to four times the size it is today?

James Lee, CEO, Hewwell AI: Yes. Again, question. I think I’ll go back to what we talked to Kevin about. There are three ways that we think about growing sort of a J curve in our IR revenue. Firstly is the number of deployments we have.

So the number of logos or users we have using that, and that’s been increasing year on year. Then the number of studies they run as a business and then the value of those studies. And so our focus is to grow both the first and the second and the third. And so as those occur, what we’re seeing is that revenue growth can be maintained. Excitingly, the value within life sciences is one element.

But as we open up the healthcare systems, we’re finding the contracting healthcare systems are across much larger bases. So the value of those contracts can be materially higher. And so what we’re seeing there is that as we go into bigger organizations, the value of the contracts can change at the same time. You’ll see us in future report on all those three measures as we put the business together. We’ve got some work to do to then articulating what’s coming what is a cross sell and what is a new opportunity.

Because as we define a healthcare system, we’ve got both life sciences partners and we’ve got healthcare systems in that mix as well. And as we talk about in future dates, there’ll be other healthcare adjacent customers that join that mix.

Hefton Seni, Investor Relations, Hewwell AI0: And of those three, which are the biggest near term challenge to get you over that hump to getting to scale? Is it new logos moving forward? Is it new logos taking on more volume per se? I mean, what right now is the one piece of the three that you think the company needs to work most on?

James Lee, CEO, Hewwell AI: As you can imagine, I’d like all three. And so the reality is we’re putting focus and energy into all three components. The healthcare sales process is a very different sales process to life sciences one. And so what we find is they don’t cannibalize each other trying to do both. Getting cleaner access and wider access to data via the Orion footprint globally is a key focus again, but it’s a different team.

What I would say to you is that we’ve focused on trying to grow all three because we know that they help each other and it becomes a very virtuous cycle rather than trying to focus on one. But to answer your question more directly, I think the most immediate growth curves will come from health care systems, given the outside nature of those contracts.

Hefton Seni, Investor Relations, Hewwell AI0: Okay. One last question for me. You talked about integrating the AI into Orion software. I’m curious how you monetize that. Is it customers opt in and then you’ll get paid for volume?

They’ll just get optionality to use that and license it. Just take me through how when AI is integrated, how that gets monetized in the total contract value?

James Lee, CEO, Hewwell AI: Yes, good question. The reality is there are a few responses like a healthcare system will have a process of how they want to deploy AI. And there’s a wide range of what customers are looking for at different components. So We’ve seen opportunities in healthcare systems wanting to deploy patient identification tools. We’re seeing customers wanting to deploy Smart Summary or Smart Search tools.

What we’ve seen is they have to go through a procurement process. The advantage we have is because we’re already embedded as a trusted partner, the procurement process with us is a very short dated process rather than going externally. So as we take our products and demonstrate them to each of our customers, we’re finding that they’ve got immediate interest in taking one of those products to go talk to the teams we’re procuring. And now from a so it won’t just be a free update, if that’s what you’re asking, they’ll have to go through an RFP process to acquire because it’s a deployment on top of, not the deployment with it.

Hefton Seni, Investor Relations, Hewwell AI: Great. Thank you.

Conference Operator: And your next question today will come from Rob Goff with Ventum. Please go ahead.

Hefton Seni, Investor Relations, Hewwell AI1: Thank you very much and congratulations on the quarter.

James Lee, CEO, Hewwell AI: Thank you, Rob.

Hefton Seni, Investor Relations, Hewwell AI1: I realize it’s not really how you’re looking at the company right now, but given the relative scale of Orion, might we look at this as what was known as Orion is a double digit growth vehicle or platform upon which you are adding incremental revenue synergies upon which you are layering on the higher growth of the AI related events. Would that be a fair characterization?

James Lee, CEO, Hewwell AI: I’m not going to comment on the numbers you threw out in terms of growth phases, but I think the way to think about it is broadly right, that we’re connecting the base layer of software. So if you think about the connecting layer that is Orion and Verasource and IntraHealth, and then we surface that data through the software, and then we provide analytical tools across the top of that through our AI capabilities. So I think that’s the best way we think about it as a stack as those three things go together. Does that answer your question?

Hefton Seni, Investor Relations, Hewwell AI1: Yes, it does. Thank you. And with respect to the RFPs, are you part of do you have partnerships in pursuing these RFPs? Or are they generally standalone applications that you are submitting?

James Lee, CEO, Hewwell AI: There’s no single answer to that. For large new countries that you’re part of the consortium, for some of them, the partnerships are internal, I. E. So of our two of our software businesses will be combining as a single entity to put into that. And some of them are just pure AI deployments at the top of their current componentry.

So there would be no need to put in an infrastructure layer.

Hefton Seni, Investor Relations, Hewwell AI1: Thank you and good luck.

James Lee, CEO, Hewwell AI: Thank you, sir.

Conference Operator: Your next question today will come from Michael Freeman with Raymond James. Please go ahead.

Anthony Lamb, CFO, Hewwell AI: Hi, everybody. Congratulations on the quarter. I’m glad really glad to see Orion load in here. I wonder if you could talk about Pentabir. I see that you’ve acquired the remaining balance of equity there.

I wonder why was now the right time to exercise that option and what does that, full ownership, enable? Does this afford you more freedom to pursue certain things?

James Lee, CEO, Hewwell AI: Excellent question. The reality is the Pentaveer acquisition was always a core component of what the team wanted to achieve. And the timing was purely because of need to scale. So what we were finding is that the Pentavir team had so many different opportunities, and the more that we were bringing to them within the Orion stack meant that we needed to provide more services right across the board. And so integrating the platforms across some of what Verisource have, what CUA have and Pentavir into a single business unit became paramount to ensure that we get better margins.

So rather than having individual deployments, we would have a single deployment as a back end to increase the margin and scalability of the product set. Because when businesses go through extreme growth, you don’t get that right early, you can give away margin long term. So that was a core component of the why now. And what it gives us now is the ability to scale the business we put it together.

Anthony Lamb, CFO, Hewwell AI: Okay. Thank you very much for that. And on a guess a similar note, but maybe an opposite note, mentioned a divestment here of the patient services and CRO businesses and it’s margins appear to be I guess business wide margins appear to be core motivating factor there. I wonder if there are other assets as you look at the business going forward, are there other assets under the Healwell umbrella that may not align with the long term vision of the company or maybe the core ethos of the company may be redundant?

James Lee, CEO, Hewwell AI: Look, I think any company has to evaluate their asset set at all times against value, right? I think that’s a core component of focusing on return on invested capital for investors. What I would say now is that we’ve got a lot on our plate. The focus point is not so much that our clinical businesses are low margin. It’s more that there’s a really large opportunity in front of them, and they need attention and investment.

And so as we think about the right thing for both those businesses, their customers, and the right thing for Healwell, it isn’t to confuse ourselves and our energies on two different very different topics. I think currently our software businesses are more likely to acquire new assets and our AI businesses acquire new skills rather than to exit them. But we also have items on balance sheet like a holding xAI, which will probably becomes non core.

Anthony Lamb, CFO, Hewwell AI: Okay. All right. That’s great. Thank you

Hefton Seni, Investor Relations, Hewwell AI2: very much. Congrats and I’ll talk to you next quarter.

Conference Operator: Your next question today will come from George Ulybischev with Clarus Securities. Please go ahead.

Hefton Seni, Investor Relations, Hewwell AI2: Hi, guys. Congrats on a good quarter and thanks for taking the questions. My first question is on Orion and CoreAI revenue and you guys kind of touched on that. But now that you guys have expanded your reach to roughly an additional 150,000,000 lives with the acquisition, How quickly and to what extent can you guys leverage this new access to data to generate core AI revenue from life science companies?

James Lee, CEO, Hewwell AI: The reality is that it’s not about speed, it’s about efforts. So what we need to do is go through the process at each end to ensure that we’ve got the same rigor we take within Canada, we can apply globally. And so we’re messaging on each of those markets currently now with our customers to ensure that speed is not foregone in the element of getting the right transparency and approvals from both the governmental levels and from the customer levels. So right now, we’re focused on doing it properly rather than doing it quickly.

Hefton Seni, Investor Relations, Hewwell AI2: Okay. Understood. Thanks, James. And then you guys also mentioned having identified several tuck in M and A opportunities. Can you share what areas of or capabilities you are prioritizing with those deals?

And how far are you with the process for those?

James Lee, CEO, Hewwell AI: Excellent. I won’t comment on the far we enter those processes purely because they’re further targets that would give them a different approach of what we’re thinking. But in terms of the types of capabilities, what we’re looking for are new capabilities in data science so that we can either open up new avenues, as you talked about, for data access or new geographies where we don’t have capability. What we want to be is quite holistic in terms of the AI offerings we bring to customers. We’ve got a broader suite of offerings, including efficiency tools within the market, including new diseases and new states, and then new geographies for our identification processes.

But Alex and the team have done a really good job over the last year and have a long list of targets. And we’ve looked at many, but we’re very disciplined of what we want to do. We don’t want to distract ourselves from an opportunity we have in front of us to do M and A, but if we can do M and A that accelerate then we’ll discuss it. Anything you want to add to that Alex?

Alexander Domonoske, President, Hewwell AI: No, I think that’s good James. I’ll just add that ’s a number of exciting opportunities, right, particularly now in the healthcare landscape and now that our footprint has expanded substantially, right. So we’re looking at opportunities in different jurisdictions. Thanks George.

Anthony Lamb, CFO, Hewwell AI: Great. That’s it from me guys. Thank you.

Conference Operator: And your next question today will come from Justin Keywood with Stifel GMP. Please go ahead.

: Good afternoon. Thanks for taking my call and nice to see the financial inflection. I’m not sure if I missed it, but on the divestiture of the CRO business and PolyClinic, any indication on the potential proceeds or range of value and timing on when one or both those divestitures could occur?

James Lee, CEO, Hewwell AI: Look, we haven’t provided that given there are a number of LOIs from different parties. We are being very mindful, be careful with what we say there, but we will update the market in the appropriate time. What I would suggest is that the Board is motivated to get the businesses focused on running the business, not run a long dated process. We’re conscious that these processes can be impactful for both staff and customers, so we want to be quick with our process.

: Great. We’ll look forward to that. And then on the synergies and the sharing of well resources, are you able just to provide some additional details on the areas within the business that could benefit from that larger platform?

James Lee, CEO, Hewwell AI: Look, the reality is, well, it’s a wonderful partner, and we’ve got and have been really supportive of accessing what we need. We’re already seeing benefits across procurement. We’re talking about things like property, the access they have to systems and platforms. What we’re finding with Well is that, as you’d expect, there’s a wonderful partner. We’ve got the world is our oyster.

It’s a phrase we’d use in New Zealand. I don’t know if that is familiar as much as it is in Canada. But the reality is we’re going through that now with a lens of what is the best interest for both parties, how can we get the right types of synergies, and how do we get that connected and well. Because again, we want to make a good decision that allows us to scale as opposed to fast decisions. So we’re going through all of those discussions right now.

First process was getting the HeWell componentry done. So it’s a single one time integration into the Well family as opposed to multiple integrations. But just even things like systems, we’re finding that there’s lovely commonality there. And certainly, the capability they have with their executive function to lean in on areas where we won’t need to hire for has been really well received.

: Absolutely. Certainly seems like lots of opportunity for efficiency. Thanks for taking my call.

Conference Operator: And your next question today will come from Gabriel Leung with Beacon Securities. Please go ahead.

Anthony Lamb, CFO, Hewwell AI: Thanks for taking my questions. Just a couple of quick follow ups. Just curious if you’re able to provide a backlog figure for your professional services business and if you can just talk about the duration of that backlog?

James Lee, CEO, Hewwell AI: Anthony, do you want to cover that one off?

Anthony Lamb, CFO, Hewwell AI: Gabe, I’d say that the backlog that we have today is similar to where we were as brought on Orion. The details around that right now we’re still better understanding because a big portion of that is coming from the Orion acquisition. So I would say more to come as we dig through some of those details and before I actually give you firm guidance on that.

James Lee, CEO, Hewwell AI: Fair enough. And then I think

Anthony Lamb, CFO, Hewwell AI: you might have covered this James, but in terms of how should we be thinking about software sale versus a professional dollar sale? How many professional dollars should we expect from any given sort of deployment?

James Lee, CEO, Hewwell AI: Again, there’s no good answer to that. They range quite from sometimes there’s three times as much professional services as is that are occurring to this one to one ratio and time. The reality is that professional services covers both new implementations, upgrades, new feature development. So I don’t think I would look at professional services as a whole as a single number. I think there are multiple ways to look at that number.

Part of it, again, is as we get more detail from the businesses and combine them is to provide more clarity to the market as to each of those individual drivers. Just to give you an instance, some of them are their embedded resource within professional services within a business unit, which therefore is more recurring in nature than professional services. Does that make sense? So one of our goals is to provide more transparency to the market of each of those components in time, but that will take us as we put them together to take it apart and reorchestrate how we explain that.

Anthony Lamb, CFO, Hewwell AI: Got you. Super helpful. And actually just one last question. I just continue to move through the integration and try to generate more synergies. How should we be thinking about the operating expense base using Q2 as the baseline?

Is it really more about leveraging what you have now to grow your revenues? Or should we anticipate some perhaps some additional small cuts to the current expense base?

James Lee, CEO, Hewwell AI: Look, that’s a really good question. I think once we take out the clinical businesses, we’ll get a better handle on what further synergies we can take out across the business. As an integrated platform, our clinical platforms cover about onethree of employees, for instance. So there’ll be some a large element there of working out, well, what would we need to support a smaller business? How do we integrate those?

My comment would be that I’d focus more on margin because as we grow, we will need to be growing our cost base as we grow globally as well. And so we’re very fixated on the margin per se relative from revenue to cost as opposed to just the underlying cost. But as a key focus point, removing costs on a stand alone basis today, if we’re so efficiently and not impacting the deployment of our current customers is a real focus.

Anthony Lamb, CFO, Hewwell AI: Got you. I appreciate the feedback and congrats on the progress.

Conference Operator: This concludes the question and answer session. I will now turn the call back to James Lee for any closing remarks.

James Lee, CEO, Hewwell AI: Thank you all for joining us. What I would encourage is I really appreciate the people that reached out to meet us and spend time with us over my first three months. I wanted to say a big thank you to Alex and Hamid for helping with the transition. Alex and I are working really well, and I would count him as a close friend now. So I’ve really enjoyed the early days with the Hewwell journey.

I’m looking forward to having more of these and in time having more in person. So thank you for joining us. Keep safe and look forward to keeping in touch.

Conference Operator: This brings to a close today’s conference call. You may now disconnect your lines. Thank you for participating and have a pleasant day.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.